Method of screening cell death inhibitor

Details Method of screening cell death inhibitor Method of screening cell death inhibitor

2006-08-29

2006-08-29

Hayes, Robert C. (Department: 1649)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S069100, C435S320100, C435S252300, C536S023500, C530S350000

Reexamination Certificate

active

07097990

ABSTRACT:
There is provided a method of screening for substance that inhibits cell death induced by activation of PARP, particularly a substance that is useful as a therapeutic and/or preventive agent for rheumatoid arthritis, neuronal death at the time of cerebral ischemia, cell death of the heart after myocardial infarction reperfusion, autoimmune destruction of β-cells of pancreatic islets of Langerhans, cell death after shock, or inflammatory reaction by immunocyte death. Also provided are a novel protein and a novel gene encoding the same. The aforementioned screening method comprises a step of allowing a test substance to contact a cell expressing an LTRPC2 protein under a conditions such that the LTRPC2 protein can be activated, and a step of analyzing inhibition of LTRPC2 protein activation. The aforementioned novel protein is a rat or mouse LTRPC2 protein, and the aforementioned novel gene is a rat or mouse LTRPC2 gene.

REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 6451602 (2002-09-01), Popoff et al.
patent: 6548272 (2003-04-01), Shimizu et al.
patent: 2002/0182635 (2002-12-01), Penner et al.
patent: 1 048 727 (2000-11-01), None
patent: WO 99/35158 (1999-07-01), None
patent: WO 00/40614 (2000-07-01), None
patent: WO 00/65056 (2000-11-01), None
patent: WO 02/38608 (2002-05-01), None
patent: WO 02/072824 (2002-09-01), None
patent: WO 02/076488 (2002-10-01), None
patent: WO 02/095010 (2002-11-01), None
patent: WO 02/102994 (2002-12-01), None
patent: WO 03/004622 (2003-01-01), None
patent: WO 03/025130 (2003-03-01), None
patent: WO 03/038063 (2003-05-01), None
patent: WO 03/073983 (2003-09-01), None
Kandel, E.R., Schwartz, J.H., and Jessell, T. Principles of Neural Science. Third Edition, 1991. New York: Elsevier Science Publishing Co., Inc.
Hille, B. Ionic Channels of Excitable Membranes. Second Edition, 1992. Sunderland, MA: Sinauer Associates.
Hopp, T.P. and Woods, K.R. (1981). Prediction of protein antigenic determinants from amino acid sequences. Proceedings of the National Academy of Sciences USA 78:3824-3828.
Vukicevic, S., Kopp, J.B., Luyten, F.P., and Sampath, T.K. 1996. Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphometric protein 7). Proceedings of the National Academies of Sciences U.S.A. 93: 9021-9026.
Alberts, B, Bray, D, Lewis, J, Raff, M, Roberts, K, Watson, JD. 1994. Molecular Biology of the Cell. Third Edition. New York: Garland Publishing, Inc.
GenBank accession No. Q91YD4.
Smith S. 2001. The world according to PARP. Trends in Biochemical Sciences 26:174-179.
Hille, B. Ionic channels of excitable membranes. 1992. Sunderland, MA:Sinauer Associates, pp. 4-19.
Marshall “Gene Therapy's Growing Pains”. Science, vol. 269 (1995), pp. 1050-1055.
Verma I.M. et al. 1997. Nature 389:239-242.
Orkin S.H. et al. 1995. “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”.
Laniel 2001. Journal of Biological Chemistry 276:20766-20773.
Shackelford 2000. Free Radical Biology and Medicine 28:1387-1404.
NCBI locus AJ344343.
Schendel 1998. Current Protocols in Molecular Biology 16.1.1-16.1.3.
UniProt Accession No. Q91YD4.
Feng Qian et al., “Candidates for Nonselective Cation Channels and Store-Operated Channels in Insulin-Secreting Cells”, Diabetes, 2002, vol. 51, Supplement 1, pp. 8183-8189.
Edith Wehage et al., “Activation of the Cation Channel Long Transient Receptor Potential Channel 2 (LTRPC2) by Hydrogen Peroxide”, Journal of Biological Chemistry, 2002, vol. 277, No. 26, pp. 23150-23156.
Anne-Laure Perraud et al., “ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology”, Nature, 2001, vol. 411, No. 6837, pp. 595-599.
“The 73rdAnnual Meeting of The Japanese Pharmacological Society Mar. 23-25, 2000 Y okohama Japan”, The Japanese Journal of Pharmacology, 2000, vol. 82, Supplemental I, p. 83.
Yorikata Sano et al., “Immunocyte Ca2+Influx System Mediated by LTRPC2”, Science, 2001, vol. 293, No. 5533, pp. 1327-1330.
Kentaro Nagamine et al., “Molecular Cloning of a Novel Putative Ca2+Channel Protein (TRPC7) Highly Expressed in Brain”, Genomics, 1998, vol. 54, pp. 124-131.
Yuji Hara et al., “LTRPC2 Ca2+-Permeable Channel Activated by Changes in Redox Status Confers Susceptibility to Cell Death”, Molecular Cell, 2002, vol. 9, pp. 163-173.
International Search Report dated Sep. 5, 2002.
Feng Qian et al., “Candidates for Nonselective Cation Channels and Store-Operated Channels in Insulin-Secreting Cells”, Diabetes, 2002, vol. 51, Supplement 1, pp. S183-S189.

Affiliated with

Also associated with

Rating

Method of screening cell death inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of screening cell death inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of screening cell death inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3695177